1. Search Result
Search Result
Results for "

RPTPβ/ζ

" in MedChemExpress (MCE) Product Catalog:

51

Inhibitors & Agonists

10

Peptides

6

Natural
Products

16

Recombinant Proteins

2

Isotope-Labeled Compounds

8

Antibodies

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-123979
    ζ-Stat
    1 Publications Verification

    NSC37044

    PKC Apoptosis Cancer
    ζ-Stat (NSC37044) is a specific and atypical PKC-ζ inhibitor, with an IC50 of 5 μM. ζ-Stat can reduce melanoma cell lines proliferation and induce apoptosis, and has antitumor activity in vitro .
    ζ-Stat
  • HY-123979A
    ζ-Stat trisodium
    1 Publications Verification

    NSC37044 trisodium

    PKC Apoptosis Cancer
    ζ-Stat trisodium (NSC37044 trisodium) is a specific and atypical PKC-ζ inhibitor, with an IC50 of 5 μM. ζ-Stat trisodium can reduce melanoma cell lines proliferation and induce apoptosis, and has antitumor activity in vitro .
    ζ-Stat trisodium
  • HY-120497

    PKC CDK Cancer
    PKCζ-IN-1 is a compound that inhibits PKCζ and CDK2, showing an IC50 value of 5.18 nM for PKCζ and 1.04 μM for CDK2, with significant selectivity of 200-fold. PKCζ-IN-1 can reduce the activity of CDK2 while inhibiting PKCζ.
    PKCζ-IN-1
  • HY-P1372

    PKC Others
    PKC ζ pseudosubstrate, a PKC ζ inhibitor peptide, can be attached to cell permeabilization vector peptide .
    PKC ζ pseudosubstrate
  • HY-129153

    Others Others
    Ganoderic acid ζ is a triterpene that can be isolated from the spores of Ganoderma lucidum .
    Ganoderic acid ζ
  • HY-N7807

    ζ2-Tocopherol

    Biochemical Assay Reagents Metabolic Disease
    (±)-5,7-Dimethyltocol (ζ2-Tocopherol) is an ester product.
    (±)-5,7-Dimethyltocol
  • HY-156573

    DGK Cancer
    DGKα&ζ-IN-1 (Compound II) is a DGK target inhibitor. DGKα&ζ-IN-1 can enhance the function of T cells, and has a synergistic effect with PD-1, which has therapeutic effects IN both immune and tumor .
    DGKα&ζ-IN-1
  • HY-156572

    DGK Cancer
    DGKζ-IN-3 is a DGK-zeta-inhibitor. DGKζ-IN-3 is used in liquid and solid cancer and other diacylglycerol kinase zeta (DGK-ζ) regulation of diseases .
    DGKζ-IN-3
  • HY-170427

    DGK Inflammation/Immunology
    DGKζ-IN-10 (compound 349) is a DGKζ inhibitor, with an IC50 ≤200 nM .
    DGKζ-IN-10
  • HY-170426

    DGK Inflammation/Immunology
    DGKζ-IN-9 (compound 73) is a DGKζ inhibitor, with an IC50 ≤200 nM .
    DGKζ-IN-9
  • HY-160123

    DGK Cancer
    DGKζ-IN-5 is a DGKζ inhibitor (WO2023125681A1; compound A27a) .
    DGKζ-IN-5
  • HY-156574

    DGK Cancer
    DGKζ-IN-4 is a DGK-zeta inhibitor. DGKζ-IN-4 can be used as an active component of pharmaceutical compositions. DGKζ-IN-4 is used to treat cancers associated with immune cell activation or cancers resistant to anti-PD-1 antibody/anti-PD-11 antibody treatment .
    DGKζ-IN-4
  • HY-P1467

    5-Methionine-enkephalin amide

    Opioid Receptor Neurological Disease
    [Met5]-Enkephalin, amide is an agonist for δ opioid receptors as well as putative ζ ζ opioid receptors.
    [Met5]-Enkephalin, amide
  • HY-169318

    DGK Interleukin Related Inflammation/Immunology Cancer
    DGKζ-IN-7 (compound 97) is an oral active DGKζ inhibitor with the IC50 of 33.4 nM. DGKζ-IN-6 inhibits the secretion of IL-2 and can be used for study of cancer and autoimmune diseases .
    DGKζ-IN-7
  • HY-169317

    DGK Interleukin Related Inflammation/Immunology Cancer
    DGKζ-IN-6 (compound 40) is an oral active DGKζ inhibitor with the IC50 of 45.5 nM. DGKζ-IN-6 inhibits the secretion of IL-2 and can be used for study of cancer and autoimmune diseases .
    DGKζ-IN-6
  • HY-P1467A

    5-Methionine-enkephalin amide TFA

    Opioid Receptor Neurological Disease
    [Met5]-Enkephalin, amide TFA is an agonist for δ opioid receptors as well as putative ζ ζ opioid receptors.
    [Met5]-Enkephalin, amide TFA
  • HY-153793

    DGK Cancer
    DGKζ-IN-1 (compound 9) is an inhibitor of DGKζ. DGKζ-IN-1 can be used for research in cancer related to immunocyte activation or cancer resistant to anti-PD-1 antibody/anti-PD-L1 antibody .
    DGKζ-IN-1
  • HY-153343
    BAY 2965501
    1 Publications Verification

    DGK Cancer
    BAY 2965501 is a potent and selective diacylglycerol kinase zeta (DGKζ) inhibitor. BAY 2965501 induces pERK activation. BAY 2965501 can be used for the research of cancer .
    BAY 2965501
  • HY-P1399

    Myr-Pep2m

    PKC Neurological Disease
    Pep2m, myristoylated (Myr-Pep2m) is a cell-permeable peptide. Pep2m, myristoylated can disrupt the protein kinase ζ (PKMζ) downstream targets, N-ethylmaleimide-sensitive factor/glutamate receptor subunit 2 (NSF/GluR2) interactions. PKMζ is an autonomously active isozyme of protein kinase C (PKC) .
    Pep2m, myristoylated
  • HY-P1399A

    Myr-Pep2m TFA

    PKC Neurological Disease
    Pep2m, myristoylated TFA (Myr-Pep2m TFA) is a cell-permeable peptide. Pep2m, myristoylated TFA can disrupt the protein kinase ζ (PKMζ) downstream targets, N-ethylmaleimide-sensitive factor/glutamate receptor subunit 2 (NSF/GluR2) interactions. PKMζ is an autonomously active isozyme of protein kinase C (PKC) .
    Pep2m, myristoylated TFA
  • HY-153343A

    DGK ERK Cancer
    (S)-BAY 2965501 is the left-handed isomer of BAY 2965501 (HY-153343). BAY 2965501 is a potent and selective diacylglycerol kinase zeta (DGKζ) inhibitor. BAY 2965501 induces pERK activation. BAY 2965501 can be used for the research of cancer .
    (S)-BAY 2965501
  • HY-P1391

    iGluR Others
    ZIP(Scrambled) is a scrambled control peptide for zeta inhibitory peptide (ZIP) .
    ZIP(Scrambled)
  • HY-P1391A

    PKC Others
    ZIP(Scrambled) TFA is a scrambled control peptide for zeta inhibitory peptide (ZIP) .
    ZIP(Scrambled) TFA
  • HY-162838

    Estrogen Receptor/ERR Others
    TCF199 is an allosteric stabilizer that stabilizes the 14-3-3/TAZ peptide interaction, binding to the 14-3-3ζ/E R α peptide and 14-3-3ζ/Chibby peptide. TCF199 has a Kd value of 122 μM for its interaction with 14-3-3/TAZ .
    TCF199
  • HY-N8301

    LL-Z 1272ζ

    Bacterial Infection
    Ilicicolin F is a fungal metabolite that has been found in Fusarium and has diverse biological activities. It inhibits T. vivax alternative oxidase and the E. coli ubiquinol oxidase cytochrome bo (IC50s=0.43 and 0.37 μM, respectively) but not the E. coli ubiquinol oxidase cytochrome bd (IC50=85 μM).2 Ilicicolin F is active against the fungi A. fumigatus and C. albicans (MICs=1.66-3.33 and 6.66-13.33 μg/mL, respectively). It is cytotoxic to HeLa cells with an EC50 value of 0.003 μg/mL.
    Ilicicolin F
  • HY-P1284
    ZIP
    1 Publications Verification

    PKC Neurological Disease Cancer
    ZIP is a selective peptide inhibitor of PKMζ. ZIP injections can block the impairment in morphine conditioned place preference induced .
    ZIP
  • HY-P3201

    Pyruvate Kinase Neurological Disease
    PKCζ/ι pseudosubstrate inhibitor has broad-spectrum effects on the PKC enzyme family and can induce memory impairment .
    PKCζ/ι pseudosubstrate inhibitor
  • HY-P1284A

    PKC Neurological Disease Cancer
    ZIP TFA is a selective peptide inhibitor of PKMζ. ZIP TFA injections can block the impairment in morphine conditioned place preference induced .
    ZIP TFA
  • HY-164905

    DGK Cancer
    DGK-IN-8 (Example 34) is a DGK inhibitor, with IC50 of ≤ 20 nM for DGKα and ζ. DGK-IN-8 can be used for cancer research .
    DGK-IN-8
  • HY-149666

    DGK Cancer
    BMS-496 is adualDGKα/ζlipid kinase inhibitor, with theIC50of 0.09 (DGKα) and 0.006 μM (DGKζ) .
    BMS-496
  • HY-149667

    DGK Cancer
    BMS-332 is adualDGKα/ζlipid kinase inhibitor, with theIC50of 0.005 (DGKα) and 0.001 μM (DGKζ) .
    BMS-332
  • HY-126214
    JH-RE-06
    2 Publications Verification

    DNA/RNA Synthesis Cancer
    JH-RE-06, a potent REV1-REV7 interface inhibitor (IC50=0.78 μM; Kd=0.42 μM), targets REV1 that interacts with the REV7 subunit of POLζ. JH-RE-06 disrupts mutagenic translesion synthesis (TLS) by preventing recruitment of mutagenic POLζ. JH-RE-06 improves chemotherapy .
    JH-RE-06
  • HY-13689
    Go 6983
    Maximum Cited Publications
    62 Publications Verification

    Gö 6983; Goe 6983

    PKC Cancer
    Go 6983 is a pan-PKC inhibitor against for PKCα, PKCβ, PKCγ, PKCδ and PKCζ with IC50 of 7 nM, 7 nM, 6 nM, 10 nM and 60 nM, respectively.
    Go 6983
  • HY-159649

    DGK Cancer
    BMS-986408 is an orally active dual DGK α/ζ inhibitor that restores T cell-mediated anti-tumor immunity by enhancing T cell signaling .
    BMS-986408
  • HY-122949

    DGK Metabolic Disease
    Momordicine I, a triterpenoid compound extracted from momordica charantia L. Momordicine I alleviates isoproterenol-induced cardiomyocyte hypertrophy through suppression of PLA2G6 and DGK-ζ .
    Momordicine I
  • HY-131220

    PKC Inflammation/Immunology
    aPKC-IN-1 (compound 1) is an atypical protein kinase C (aPKCζ) inhibitor. aPKC-IN-1 can be used for the study of a host of diseases involving increased vascular permeability and inflammation .
    aPKC-IN-1
  • HY-18713A

    PKC ROCK Neurological Disease
    CRT0066854 hydrochloride is a potent and selective atypical PKCs inhibitor. CRT0066854 is against full-length (FL) PKCι, PKCζ, and ROCK-II kinases with IC50 values of 132 nM, 639 nM, and 620 nM, respectively .
    CRT0066854 hydrochloride
  • HY-126214S

    DNA/RNA Synthesis Cancer
    JH-RE-06-d6 is deuterium labele JH-RE-06. JH-RE-06, a potent REV1-REV7 interface inhibitor (IC50=0.78 μM; Ki=0.42 μM), targets REV1 that interacts with the REV7 subunit of POLζ. JH-RE-06 disrupts mutagenic translesion synthesis (TLS) by preventing recruitment of mutagenic POLζ. JH-RE-06 improves chemotherapy .
    JH-RE-06-d6
  • HY-18713

    PKC ROCK Neurological Disease Inflammation/Immunology
    CRT0066854 is a potent and selective atypical PKC isoenzymes inhibitor. CRT0066854 is against full-length (FL) PKCι, PKCζ, and ROCK-II kinases with IC50 values of 132 nM, 639 nM, and 620 nM, respectively .
    CRT0066854
  • HY-113622

    Palmarumycin C13; Diepoxin ζ; Antibiotic Sch53514

    Fungal Antibiotic Infection
    Cladospirone bisepoxide is a metabolite that isolated from cultures of a fungus. Cladospirone bisepoxide displays selective antibiotic activity against several bacteria and fungi and inhibits germinations of Lepidium sativum at low concentrations .
    Cladospirone bisepoxide
  • HY-13626

    ES-285

    PKC Apoptosis Cancer
    Spisulosine (ES-285) is an antiproliferative (antitumoral) compound of marine origin. Spisulosine inhibits the growth of the prostate PC-3 and LNCaP cells through intracellular ceramide accumulation and PKCζ activation. Spisulosine induces apoptosis in PC-3 and LNCaP cells .
    Spisulosine
  • HY-117366

    PKC Cancer
    PS432 is a PKC inhibitor with IC50s of 16.9 μM (PKCι) and 18.5 μM (PKCζ), respectively. PS432 effectively inhibits the proliferation of non-small cell lung cancer cells (NSCLCs) and tumor growth in mouse xenograft models .
    PS432
  • HY-136179
    ZAP-180013
    1 Publications Verification

    Tyrosinase Inflammation/Immunology
    ZAP-180013 is a zeta-chain-associated protein kinase 70 (ZAP-70) inhibitor with an IC50 of 1.8 μM. ZAP-180013 inhibits the interaction of ZAP-70 SH2 domain with immunoreceptor tyrosine-based activation motif (ITAMs) .
    ZAP-180013
  • HY-149874

    DGK Inflammation/Immunology Cancer
    BMS-502 (Compound 22) is a potent dual inhibitor of diacylglycerol kinase (DGK) α and ζ with IC50 of 4.6 nM and 2.1 nM. BMS-502 enhanced T cell immune responses in mice. BMS-502 can be used in tumor immunity related research .
    BMS-502
  • HY-13626S

    ES-285-d3

    Isotope-Labeled Compounds PKC Apoptosis Cancer
    Spisulosine-d3 (ES-285-d3) is deuterium labeled Spisulosine (HY-13626). Spisulosine is an antiproliferative (antitumoral) compound of marine origin. Spisulosine inhibits the growth of the prostate PC-3 and LNCaP cells through intracellular ceramide accumulation and PKCζ activation. Spisulosine induces apoptosis in PC-3 and LNCaP cells .
    Spisulosine-d3
  • HY-123966

    Phosphatase Neurological Disease
    MY33-3 is a potent and selective inhibitor of receptor protein tyrosine phosphatase (RPTP)β/ζ, with an IC50 of ~0.1 μM. MY33-3 also inhibits PTP-1B (IC50 ~0.7 μM). MY33-3 can reduce ethanol consumption and alleviate Sevoflurane-induced neuroinflammation and cognitive dysfunction .
    MY33-3
  • HY-123966A

    Phosphatase Neurological Disease
    MY33-3 hydrochloride is a potent and selective inhibitor of receptor protein tyrosine phosphatase (RPTP)β/ζ, with an IC50 of ~0.1 μM. MY33-3 hydrochloride also inhibits PTP-1B (IC50 ~0.7 μM). MY33-3 hydrochloride can reduce ethanol consumption and alleviate Sevoflurane-induced neuroinflammation and cognitive dysfunction .
    MY33-3 hydrochloride
  • HY-124308

    PKC Cancer
    PS315, a derivative of PS48 (HY-15967), is an allosteric PKC inhibitor by binding to the PIF-pocket of aPKC and inducing a displacement of the active site residue Lys111. PS315 inhibits the full-length and catalytic domain constructs of PKCζ (IC50=10 μM) and PKCη (IC50=30 μM). PS315 has anti-cancer activity .
    PS315
  • HY-123856

    Phosphatase NF-κB c-Met/HGFR Anaplastic lymphoma kinase (ALK) Cardiovascular Disease Neurological Disease
    MY10 is a potent and orally active receptor protein tyrosine phosphatase (RPTPβ/ζ) inhibitor. MY10 reduces NF-κB p65 expression. MY10 activates tyrosine phosphorylation of c-Met. MY10 prevents the alcohol-induced downregulation of Ptprz1 and Alk expression. MY10 attenuates binge-like ethanol consumption and ethanol reward. MY10 can be used in the study of neurological and vascular diseases .
    MY10
  • HY-121197

    Ophiocordin; Azepinostatin

    MARCKS PKA PKC Others
    Balanol (Ophiocordin; Azepinostatin) is a potent and ATP competitive PKC/PKA inhibitor against human PKC isozymes α, β-I, β-II, γ, δ, ε, η (IC50s=4-9 nM) and ζ (IC50=150 nM). Balanol also blocks the phosphorylation of cyclic AMP response element-binding protein (CREB) and myristoylated alanine-rich C kinase substrate (MARCKS). Balanol can be isolated from the fungus Verticillium balanoides .
    Balanol

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: